H.C. Wainwright analyst Matthew Caufield moved its rating on Aldeyra Therapeutics to Under Review after the company received late-cycle review minutes from the FDA related to the application for reproxalap in the topical treatment of signs and symptoms of dry eye disease.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALDX: